Premium
The combination of external beam radiotherapy and experimental radioimmunotargeting with a monoclonal anticytokeratin antibody
Author(s) -
Johansson Amanda,
Eriksson David,
Ullén Anders,
Löfroth PerOlov,
Johansson Lennart,
RiklundÅhlström Katrine,
Stigbrand Torgny
Publication year - 2002
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.10302
Subject(s) - radiation therapy , monoclonal antibody , external beam radiotherapy , medicine , nuclear medicine , radioimmunotherapy , antibody , cancer research , immunology , brachytherapy
BACKGROUND Doses to tumors of up to 80 grays (Gy) have been postulated to eradicate solid experimental tumors with radiommunotargeting,, but this value has proved difficult to reach. Combining two treatment modalities, external beam radiotherapy and radioimmunotargeting, could potentially give rise to a number of advantages. METHODS The purpose of this study was to detect potential benefits with different treatment timing strategies when combining external beam radiotherapy and radioimmunotargeting, with the anticytokeratin monoclonal antibody (MAb) TS1 injected into a nude mouse model carrying subcutaneous human HeLa Hep 2‐cell tumors. Cytokeratins are present in necrotic regions within tumors, thereby providing a potential increase in binding sites for TS1 if combined with external beam radiotherapy. External beam radiotherapy was given before, after, and simultaneously with injection of radiolabeled MAb. RESULTS The highest yields in terms of total accumulated dose (Gy), percentage of injected activity per gram of tumor tissue, and accumulated dose per injected activity (Gy/MBq) were seen in the group receiving external beam radiotherapy prior to MAb‐injection. CONCLUSIONS Enhanced effects may be achievable by combining external beam radiotherapy with experimental radioimmunotargeting using the monoclonal anticytokeratin antibody TS1, if the radiotherapy is given prior to MAb injection. Cancer 2002;94:1314–9. © 2002 American Cancer Society. DOI 10.1002/cncr.10302